Clinical Trials Logo

Filter by:
NCT ID: NCT05444179 Not yet recruiting - Clinical trials for Postpartum Depression

Nutrition and Physical Activity Intervention on Psychosocial Well-Being of Postpartum Mothers

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study aims to examine the effectiveness of nutrition and physical intervention to improve psychosocial well-being of postpartum mothers with preterm infants. The focus was highlighted towards the mothers of preterm infants who were cared in Neonatal Intensive Care Unit (NICU) as these parents might have a higher stress level than the full-term infants. The intervention consisted of a module designed for postpartum mothers, incorporating nutrition and physical activity entitled Mommies can Eat & Exercise with No Stress (MomEENS).

NCT ID: NCT05445388 Not yet recruiting - Image, Body Clinical Trials

Feasibility of Middle Ear OCT Imaging

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Feasibility of structural and functional imaging of the middle ear and its constituents by optical coherence tomography.

NCT ID: NCT05445401 Not yet recruiting - Gastric Cancer Clinical Trials

Pre-rehabilitation in Neoadjuvant Patients With Gastric Cancer

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

In this study, patients with traditional neoadjuvant gastric cancer were used as controls to explore whether the triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period before surgery could improve the functional reserve of neoadjuvant gastric cancer patients and accelerate postoperative recovery.

NCT ID: NCT05446428 Not yet recruiting - Clinical trials for Elevated Level of IFN Type I in SLE Patients

Evaluation of Type I IFN Level and Disease Activity in SLE Patients

Start date: August 1, 2022
Phase:
Study type: Observational

Elevated level of IFN type I in SLE patients associated with certain serum biomarkers (galectin -1,-3,-9; cytokine profile - 20 plex panel - GM-CSF, IFN-γ, IL-2, -4,-5,-6,-7,-8,-10,-13,-15,-17,-18, IP-10. MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, TNF-RII, BAFF, APRIL), clinical and laboratory manifestations, activity and duration pf the disease and SLE patients quality of life. Standard immunosuppressive and anti-B-cell therapy can reduce the IFN type I and associated biomarkers levels in patients with high and moderate disease activity (SLEDAI-2К ≥6).

NCT ID: NCT05450614 Not yet recruiting - Clinical trials for Depressive Disorder, Major

Smartphone App Based CBT Versus Online Group CBT: Randomized, Non-inferiority Clinical Trial

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The present research project aims to compare the efficacy and safety of an intervention based on a smartphone application, which uses CBT techniques, to online group cognitive behavioral therapy (CBCT), in improving depressive symptoms. The project also has supplemental analysis to predict who will respond to the CBT intervention using the application. For this analysis, machine learning algorithms, a set of techniques from the field of artificial intelligence, will be used to create a predictive calculator for response to interventions. The analysis protocol used for this analysis will be in accordance with that proposed in task Force of the International Society for Bipolar Disorders.

NCT ID: NCT05451056 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

breakthrough
Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

Lung cancer is the most common type of cancer occurring in both males and females worldwide (WHO statistics, 2018), and the 5-year survival rate for advanced NSCLC is low (between 6% and 33%, depending on the stage. The rat sarcoma (RAS) proto-oncogene has been identified as an oncogenic driver of tumorigenesis in several cancers, including NSCLC. The RAS proteins can be mutationally activated at codons 12, 13, or 61, leading to human cancers. Different tumor types are associated with mutations in certain isoforms of RAS, with Kirsten rat sarcoma viral oncogene homolog (KRAS) being the most frequently mutated isoform in most cancers. While the role of KRAS mutations in human cancers has been known for decades, no anti-cancer therapies specifically targeting KRAS mutations have been successfully developed, largely because the protein has been intractable for inhibition by small molecules. AMG 510 is a small molecule that specifically and irreversibly inhibits the KRAS G12C mutated protein. Nonclinical studies of AMG 510 have demonstrated inhibition of growth and regression of cells and tumors harboring KRAS p.G12C, and in clinical Study 20170543, AMG 510 demonstrated antitumor activity in KRAS p.G12C mutated NSCLC. These data suggest that inhibition of KRAS G12C may have therapeutic benefit for subjects with KRAS p.G12C driven cancers. Recently development of liquid biopsy technology has enabled detection of KRAS-driven cancer with plasma ctDNA analysis. Therefore, in this study, we aim to conduct a phase 2 trial of sotorasib in KRAS G12C mutant-patients, and conduct pre-treatment and post-treatment biopsies using tissue and liquid to identify novel mechanisms of acquired resistance to sotorasib in these patients. Total sample size is 37 patients, Sotorasib will be given 960mg daily until disease progression or unacceptable toxicity.

NCT ID: NCT05451433 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome

The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study aims to compare the effectiveness of Saccharomyces Boulardii vs Placebo in patient with Irritable Bowel Syndrome

NCT ID: NCT05452083 Not yet recruiting - Breast Cancer Clinical Trials

Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation.

Start date: August 1, 2022
Phase:
Study type: Observational

Evaluation of treatment toxicity of extreme hypofractionation of the whole breast in five fractions of 5.2 Gy in five consecutive workdays.

NCT ID: NCT05452759 Not yet recruiting - Pneumonia Clinical Trials

Research of Spiral Exhalation Device Oxygen Therapy to Improve the Treatment Effect of Patients With Severe Pneumonia

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Severe pneumonia has a high morbidity and mortality. Humidified oxygen therapy, mechanical ventilation, and removal of airway secretions are the main non-drug treatments. However, mechanical ventilation leads to a high economic burden, and ventilator-associated pneumonia may increase patient mortality. Therefore, it is necessary to conduct in-depth research on early release from the ventilator and oxygen therapy. Studies have shown that high-flow nasal oxygen therapy (HFNC) improves airway humidification and oxygenation in patients. The respiratory humidification therapy device (AIRVOTM2) is mainly used internationally, but clinical studies on artificial airway patients are limited. In the previous study, we improved the "New Artificial Airway High Flow Humidification Oxygen Therapy Device" (NTHF) to improve the accuracy of gas flow rate, and unified the baseline with AIRVOTM2. The status quo of the obvious differences in the airway humidification effect of patients. The pre-experiment again found that the gas flow rate consumption was significantly lower than that of AIRVOTM2 after the NTHF exhalation port was optimized, and the gas flow rate was proportional to the inhaled gas humidity. Based on this, we hypothesized that the flow rate of the optimized expiratory port of NTHF is more stable than that of AIRVOTM2, which can improve the airway humidification effect of patients. We intend to adopt a randomized controlled clinical study design, by comparing the application of two oxygen therapy devices in patients with severe pneumonia artificial airway, to explore whether NTHF can promote the clearance of airway secretions in patients with severe pneumonia and improve the therapeutic effect of severe pneumonia. Oxygen therapy nursing mode in patients with severe pneumonia artificial airway.

NCT ID: NCT05455853 Not yet recruiting - Constipation Clinical Trials

Effect of Bilateral Transcutaneous Tibial Nerve Stimulation on Postpartum Constipation

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study will be conduct to determine the effect of bilateral transcutaneous tibial nerve stimulation on treating postpartum constipation